Disease morbidity and progression are made more burdensome by the lack of a suitable dosage form for oral administration, primarily because of inadequate solubility and permeability properties of the drug. This is especially true for cancer chemotherapy. As a result, injectable dosage forms are administered which has greater risks of toxicity, discomfort to the patient, complexity of use and associated health care costs. Transporter-targeting strategies for oral drug delivery are especially important in the pharmaceutical industry since the chemical space of recent drug discovery efforts is trending toward more hydrophilic new chemical entities, primarily because of the toxicity and CYP-mediated drug-drug interactions observed with lipophilic drugs. Thus, prodrug strategies have been utilized to overcome undesirable physical-chemical properties of the drug, and to improve oral bioavailability. In particular, many studies have addressed the use of amino acid ester prodrugs for the improved delivery of anti-viral and anti-cancer agents. However, little attention has focused on the activation process and, in particular, the use of activity-based protein profiling as a tool for identifying the serine hydrolases (SHs) responsible for hydrolyzing amide, ester and thioester bonds in small molecule substrates. It is clear that new paradigms are needed to improve the intestinal absorption and bioavailability of polar (i.e., BCS Class III) therapeutic agents, and to translate these findings in a relevant animal model prior to testing in humans. Thus, the long-term objectives of this grant application are to develop orally administered prodrugs that are effective in treating cancer patients. Our working hypothesis is that the PEPT1-targeted approach in humanized mice, coupled to the chemoproteomic strategy for prodrug activation, will be effective in generating novel prodrugs for oral administration of te anti-cancer compound gemcitabine. To test this hypothesis, the following specific aims are proposed:
Aim 1. To characterize the intestinal permeability and oral absorption of the prodrug valacyclovir in a mouse model humanized for PEPT1 and determine if a species difference exists between the human and mouse PEPT1 orthologs, Aim 2. To determine the prodrug binding protein expression of serine hydrolases in the intestine and liver using advanced activity based protein profiling (ABPP) mass spectrometry-based proteomics, and Aim 3. To determine the transport and activation pathways of gemcitabine prodrugs for the development of orally administrable cancer compounds. By combining molecular, genetic, activity-based protein profiling, and whole animal studies in humanized (and transgenic) mice, the proposed studies will greatly advance our understanding of hPEPT1- targeted uptake and activation of ester prodrugs and the development of new orally available compounds to treat cancer.

Public Health Relevance

This project will develop orally available prodrugs for the treatment of cancer by utilizing novel protein targets for intestinal absorption followed by enzymatic activation to the active drug species.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM115481-01
Application #
8942916
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Okita, Richard T
Project Start
2015-08-15
Project End
2019-05-31
Budget Start
2015-08-15
Budget End
2016-05-31
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Song, Feifeng; Yi, Yaodong; Li, Cui et al. (2018) Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage. Cell Death Dis 9:770
Wang, Yuqing; Hu, Yongjun; Li, Ping et al. (2018) Expression and regulation of proton-coupled oligopeptide transporters in colonic tissue and immune cells of mice. Biochem Pharmacol 148:163-173
Bhatnagar, Sumit; Verma, Kirti Dhingra; Hu, Yongjun et al. (2018) Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening. Mol Pharm 15:1746-1754
Epling, Daniel; Hu, Yongjun; Smith, David E (2018) Evaluating the intestinal and oral absorption of the prodrug valacyclovir in wildtype and huPepT1 transgenic mice. Biochem Pharmacol 155:1-7
Wang, Xiao-Xing; Li, Yang-Bing; Feng, Meihua R et al. (2018) Semi-Mechanistic Population Pharmacokinetic Modeling of L-Histidine Disposition and Brain Uptake in Wildtype and Pht1 Null Mice. Pharm Res 35:19
Hu, Yongjun; Song, Feifeng; Jiang, Huidi et al. (2018) SLC15A2 and SLC15A4 Mediate the Transport of Bacterially Derived Di/Tripeptides To Enhance the Nucleotide-Binding Oligomerization Domain-Dependent Immune Response in Mouse Bone Marrow-Derived Macrophages. J Immunol 201:652-662
Hu, Yongjun; Epling, Daniel; Shi, Jian et al. (2018) Effect of biphenyl hydrolase-like (BPHL) gene disruption on the intestinal stability, permeability and absorption of valacyclovir in wildtype and Bphl knockout mice. Biochem Pharmacol 156:147-156
Song, Feifeng; Hu, Yongjun; Wang, Yuqing et al. (2018) Functional Characterization of Human Peptide/Histidine Transporter 1 in Stably Transfected MDCK Cells. Mol Pharm 15:385-393
Wang, Xiao-Xing; Hu, Yongjun; Keep, Richard F et al. (2017) A novel role for PHT1 in the disposition of l-histidine in brain: In vitro slice and in vivo pharmacokinetic studies in wildtype and Pht1 null mice. Biochem Pharmacol 124:94-102
Colas, Claire; Masuda, Masayuki; Sugio, Kazuaki et al. (2017) Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1. Mol Pharm 14:4685-4693

Showing the most recent 10 out of 18 publications